Document is current

Article History

Received: 31 October 2025

Revised: 25 November 2025

Accepted: 17 December 2025

First Online: 3 January 2026

Declarations

:

: The study protocol, along with all relevant documents, were reviewed and approved by the Independent Ethical Committee (IEC) or Institutional Review Board (IRB) of Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur, Rajasthan, India (Approval no. BMH/2023/3719, dated May 27, 2023) and written informed consent was obtained from all participants before they are enrolled. The study was conducted in accordance with approved protocol, ethical principles of Declaration of Helsinki (Fortaleza, Brazil, October 2013), New Drugs and Clinical Trials Rules, 2019 (Central Drugs Standard Control Organization, Ministry of Health & Family Welfare, Government of India), International Conference on Harmonization (ICH) E6 (R2) guideline on Good Clinical Practice (GCP) and any other applicable regulatory authorities.

: Consent for publication was obtained from all authors, the participants or legally authorized representatives involved in this study.

: The authors certify that informed consent was obtained from patients for being included in the study.

: The authors declare no competing interests.

: We, all the authors, declare that no generative AI or AI-assisted technologies have been utilized during drafting this manuscript.